Patrick Hwu: Inhibiting MDK could be a valuable strategy to improve immunotherapy outcomes in melanoma
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a shared an article by Marisol Soengas, et al. on X:
“Melanoma secretes a protein called midkine (MDK), which plays a key role in reprogramming dendritic cells in the tumor microenvironment.
How can this impact immune responses?
In this study by Marisol Soengas et al., MDK was shown to induce immune suppression by altering dendritic cell function. This impaired the ability of the immune system to effectively target and eliminate melanoma cells, allowing the tumor to progress.
Targeting MDK in preclinical models restored dendritic cell function, enhanced the activation of cytotoxic T cells, and improved antitumor immune responses.
This study suggests that inhibiting MDK could be a valuable strategy to improve immunotherapy outcomes in melanoma!”
Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade
Authors: Xavier Catena, Marisol Soengas, et al.
More posts featuring Patrick Hwu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023